Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Net Income (2016 - 2025)

Historic Net Income for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $28.2 million.

  • Arrowhead Pharmaceuticals' Net Income rose 11611.82% to $28.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $233.5 million, marking a year-over-year increase of 13595.3%. This contributed to the annual value of $30.1 million for FY2025, which is 10493.92% up from last year.
  • According to the latest figures from Q4 2025, Arrowhead Pharmaceuticals' Net Income is $28.2 million, which was up 11611.82% from $16.1 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' 5-year Net Income high stood at $367.8 million for Q1 2025, and its period low was -$178.7 million during Q2 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' median Net Income value was -$67.7 million (recorded in 2021), while the average stood at -$52.9 million.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Net Income tumbled by 36637.3% in 2024, and later soared by 38962.8% in 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Net Income (Quarter) stood at -$62.9 million in 2021, then soared by 33.5% to -$41.8 million in 2022, then crashed by 223.78% to -$135.4 million in 2023, then fell by 29.43% to -$175.2 million in 2024, then soared by 116.12% to $28.2 million in 2025.
  • Its Net Income stands at $28.2 million for Q4 2025, versus $16.1 million for Q3 2025 and -$178.7 million for Q2 2025.